ALK alterations (comprising activating mutations, amplifications, and fusions/rearrangements) occur in ~3.3% of cancers.1-3 In contrast, ALK fusions/rearrangements are detected in ~0.2%-0.8% of cancers overall, with varying frequencies in different malignancies (3–7% of non-small cell lung cancer [NSCLC] vs 0.2% of non‐NSCLC tumors; >50% of inflammatory myofibroblastic tumors [IMTs] and anaplastic large cell lymphomas [ALCLs]).1-4. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.